Clinical Trials

Chance Pharma Advances First NDA Submission In China For Innovative Asthma Therapy CXG87

Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhala...

 May 11, 2026 | News

Rznomics Secures FDA RMAT Designation For RNA Editing Therapy RZ 001 In Liver Cancer

RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, ...

 May 11, 2026 | News

Harbour BioMed Secures US FDA Clearance For Phase I Trial Of Bispecific Cancer Antibody HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

 May 11, 2026 | News

ABEC Expands Process Sciences Capabilities To Accelerate Bioprocess Development And Scale Up

 ABEC, a global leader in bioprocess engineering solutions, announced the expansion of its Process Sciences group, expanding its ability to ...

 May 08, 2026 | News

Taimei Technology And C&R Research Partner To Advance AI Driven Clinical Trial Operations In South Korea

Taimei Technology (HK.02576), a leading AI-powered drug clinical development platform company, and C&R Research (A359090), a top-tier CRO in South Kore...

 May 08, 2026 | News

Alebund Completes Global Phase III Enrollment For AP301 In Hyperphosphatemia Trial

Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies...

 May 07, 2026 | News

Cellenkos Advances CK0802 Into Phase 1b 2a Trial Following FDA Clearance For Steroid Refractory GVHD

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with s...

 May 06, 2026 | News

EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma

EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...

 May 05, 2026 | News

Australia Approves First RNAi Therapy For Familial Chylomicronemia Syndrome

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed a...

 May 05, 2026 | Report

Huahui Health And BeOne Medicines Forge Global Deal For Trispecific Antibody HH160

Huahui Health announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a...

 May 04, 2026 | News

Restore Vision Reports Encouraging Phase I II Data For RV 001 Gene Therapy In Retinitis Pigmentosa

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key Ma...

 May 04, 2026 | News

Lakewood Amedex Advances Nu 3 Bisphosphocin Candidate With Strong AMR Resistance Profile

Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins® Lakewood-Amedex Biotherapeutics Inc., (NASD...

 May 04, 2026 | News

Sonire Therapeutics Initiates SUNRISE II Trial To Advance Non Invasive HIFU Therapy For Pancreatic Cancer In The United States

SUNRISE-II feasibility trial marks the company's entry into U.S. clinical development, advancingminimally invasive, anesthesia-free treatment approach Son...

 May 04, 2026 | News

Formosa Pharmaceuticals And SERI Partner To Advance Next Generation Ophthalmic Therapies

    The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative ...

 May 01, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close